EGFR-Mutant NSCLC

Therapeutic Indication

Iza Bren Extends Progression Control After EGFR Therapy

The China Phase III PANKU-Lung01 trial reported a substantial blinded-review PFS gain for the EGFR×HER3 bispecific ADC izalontamab brengitecan versus platinum chemotherapy after EGFR TKI progression. The data were presented and published online in…

admin
October 26, 2026

Therapeutic Indication

SANOVO Tests Early EGFR and MET Dual Blockade

New Phase III data presented on 26 October show a large progression-free survival benefit from savolitinib plus osimertinib over osimertinib alone in untreated EGFR-mutant, MET-overexpressing advanced NSCLC in China. Overall-survival findings are promising but…

admin
October 26, 2026

Iza Bren Extends Progression Control After EGFR Therapy

SANOVO Tests Early EGFR and MET Dual Blockade

Saturday Rounds